Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 6, 24 | -0.66 Increased by +9.59% | -0.68 Increased by +2.94% |
Feb 26, 24 | -0.64 Increased by +30.43% | -0.79 Increased by +18.99% |
Nov 6, 23 | -0.75 Increased by +13.79% | -0.81 Increased by +7.41% |
Aug 9, 23 | -0.82 Increased by +1.20% | -0.79 Decreased by -3.80% |
May 4, 23 | -0.73 Decreased by -8.96% | -0.85 Increased by +14.12% |
Feb 27, 23 | -0.92 Decreased by -33.33% | -0.80 Decreased by -15.00% |
Nov 3, 22 | -0.87 Decreased by -10.13% | -0.79 Decreased by -10.13% |
Aug 8, 22 | -0.83 Decreased by -50.91% | -0.68 Decreased by -22.06% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 23 | 10.31 M Increased by +N/A% | -59.66 M Increased by +7.31% | Decreased by -578.55% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -61.90 M Decreased by -8.55% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by N/A% | -65.70 M Decreased by -20.34% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0.00 Decreased by N/A% | -54.94 M Decreased by -26.60% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0.00 Decreased by N/A% | -64.36 M Decreased by -45.47% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0.00 Decreased by N/A% | -57.02 M Decreased by -13.78% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0.00 Decreased by N/A% | -54.59 M Decreased by -58.13% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0.00 Decreased by N/A% | -43.40 M Decreased by -8.02% | Decreased by N/A% Decreased by N/A% |